drugset / Trial / NCT05448820
YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, open label, Phase 1/2 study of YH001 initially given in combination with envafolimab, and then given in combination with envafolimab plus doxorubicin in patients with advanced or metastatic sarcoma, followed by Phase 2 cohorts of patients with select histologies of advanced or metastatic sarcoma.
Timeline
- Start
- 2022-11-14
- Primary completion
- 2023-11
- Completion
- 2025-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | Envafolimab | Monoclonal antibody | — | — |
| Subject | YH001 | Unknown | — | — |